Prostate Cancer Therapeutics - Global Strategic Business Report

Description: The report provides separate comprehensive analytics for the US, Canada, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Prostate Cancer Therapeutics in US$ Million by the following Segments: Hormone Therapy, and Other Therapies.

Company profiles are primarily based on public domain information including company URLs. The report profiles 76 companies including many key and niche players such as -

AbbVie, Inc.
Æterna Zentaris Inc.
Allergan plc
Amgen Inc.
Astellas Pharma Inc.

Contents: PROSTATE CANCER THERAPEUTICS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Hormone Therapy
Other Therapies
Radiation Therapy
Immunotherapy
Chemotherapy

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW
Rising Incidence of Prostate Cancer: Cornerstone for the Market
Table 1: Prostate Cancer Incidence Worldwide: Comparative Analysis for the years 2004, 2007, and 2012 (includes corresponding Graph/Chart)
Current & Future Analysis
Market Outlook & Trends
Zytiga (Abiraterone acetate): The Market Leader
Table 2: Global Prostate Cancer Therapeutics by Leading Drug (2015): Percentage Market Share Breakdown of Value Sales for Zytiga, Xtandi, Lupron, Zoladex, Taxotere, Jevtana, Xofigo & Others (includes corresponding Graph/Chart)
Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC): 2016
Hormone Therapies to Dominate Global Prostate Cancer Therapeutics Market
Key Prostate Cancer Hormone Therapy Drugs & Companies: 2016
Targeted Therapy
The New Frontier of Cancer Treatment
Radiotherapy
Gaining Prominence
Metastatic Prostate Cancer
Apt for Precision Oncology
Demographics & Lifestyles Raise the Risk of Prostate Cancer
Table 3: Probability of Developing Invasive Prostate Cancer by Age Group in the US (includes corresponding
Table 4: Male Population by Age Group in the US for the year 2014 (includes corresponding Graph/Chart)
Select General Risk Factors and their Relative Risk Rate in Prostate Cancer
Cost Analysis of Currently Available Treatment
Table 5: Prices of Xtandi by Country (2016): Prices of Xtandi 40 mg Capsule/Tabs in the US and Other High-Income Countries (includes corresponding Graph/Chart)
Growth Drivers
Rise in Prostate Cancer Incidence & Access to Modern Therapeutics Foster Growth
Table 6: New Cancer Cases Diagnosed in the US by Site (2016): Percentage Share of Leading Cancer Sites (includes corresponding Graph/Chart)
Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
Table 7: Five-Year Prostate Cancer Survival Rate (%) Among US Males (2005-2011)
Awareness Drives European Prostate Cancer Therapeutics Market
Minimally Invasive Devices to Gain Share in Emerging Markets
Supportive Cancer Drugs Contribute to Growth
Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer
Developments in Proteomics Favor Market
Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
Growth Restraints
Costly & Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
Limited Tumor Specificity and Toxicity
Multiple Drug Resistance
Stringent Regulations Delay Market Approval
Challenges Faced by Patients and Clinicians in Diagnosis and Treatment
Challenges Encountered in Clinical Trials
Select Recent Prostate Cancer Drug Trial Failures (As of 2016)
High Development Costs Retracts Manufacturers in Developing Countries
Pipeline of Drugs in Clinical Trials
New Products to Bolster Sales of Prostate Cancer Therapeutics
Select Prostate Cancer Drugs in the Pipeline (2016)
Marine Sponge-Derived Compound Shows Promise against Prostate Cancer
New Combination Treatment for Advanced mCRPC
Risk of Alzheimer’s dampens the Market
Innovations & Advancements
Research and Development Findings
Additional Tests to be used with PSA for Better Diagnosis of Prostate Cancer
New Approaches in Diagnosis and Staging of Prostate Cancer
New Developments in Treatment Methods and Diet Strategies
Innovative mCRPC Treatment Options to Enhance Quality of Life
New Drug Class (sphingolipid pathway inhibitor) Shows Potential for Slowing down Growth
Neural Stem Cell Therapy: Revolutionary Step to Combat Cancer
Combination of Therapies under Research
Future Research Strategies to Benefit from Open Access Publishing
Innovations in Drug Delivery: A Key Factor in Product Differentiation

2. PRODUCT OVERVIEW
Cancer: A Major Health Crisis in the Modern World
Prostate
Structure
Pituitary Gland
Testes
Prostate Cancer
A Primer
Key Facts
Table 8: Lifetime Probability of Developing Prostate Cancer by Age (%) 2010-2012 (includes corresponding Graph/Chart)
Table 9: New Incidence Rate of Prostate Cancer (Rate per Million Population) Worldwide for 2012 (includes corresponding Graph/Chart)
Screening/Detection of Prostate Cancer
Digital Rectal Exam (DRE)
Transrectal Ultrasound (TRUS)
PSA Blood Test
Strategies to Enhance Screening/Detection of Prostate Cancer
Improved PSA Testing
Total PSA, Free PSA and PSA-Alpha-1-Protease Inhibitor Levels
Insulin-like Growth Factor (IGF-1) and Intact IGF-Binding Protein-3 (IGF-BP3)
GSTP1 Methylation Levels and Prostate Cancer Diagnosis
Microbubble Ultrasound
Staging of Prostate Cancer
Gleason Score
Gleason Score and Grading of Prostate Cancer
TNM Staging
T-Staging Analysis of Prostate Cancer
Genetic & Non-Genetic Factors
Hereditary or Genetic Factors
Non-Genetic or Environmental Factors
Table 10: Prostate Cancer Incidence/Mortality Rate in the US by Ethnicity (2008-2012) (includes corresponding Graph/Chart)
Prevention of Cancer
Role of Diet in Prostate Cancer
Treatment Options for Prostate Cancer
Hormonal Therapy
Medical Hormone Therapy
LHRH Analogs
Dose of LHRH Agonists for Advance Prostate Carcinoma Treatment
Anti-Androgens
Anti-Androgen Monotherapy
Orchiectomy
Side Effects of Orchiectomy
Time to Start Hormonal Therapy
Strategies to Enhance Hormonal Treatment
Combination Therapy
Intermittent Therapy
Radiation Therapy
Brachytherapy
Treatment Procedure
Benefits of Brachytherapy
Drawbacks of Brachytherapy
High Dose Rate (HDR) Brachytherapy
External Beam Radiation Therapy (EBRT)
Side Effects of Radiotherapy
Strategies to Enhance Radiation Treatment
Chemotherapy
Risks Associated with Chemotherapy
Surgical Procedures for Prostate Cancer
Transurethral Resection of the Prostate (TURP)
Prostatectomy and Lymph Node Dissection
Radical Prostatectomy
Cryosurgery
Advantages of Cryosurgery:
Disadvantages of Cryosurgery:
Other Treatment Options
Intensity Modulated Radiation Therapy (IMRT)
Benefits of IMRT
Drawbacks of IMRT
Androgen Deprivation Therapy (ADT)
High Dose Radiation (HDR) Monotherapy
Drawbacks of HRD
Choosing the Optimal Treatment Method
Recurrent Prostate Cancer
Recurrent Prostate Cancer Subsequent to Surgery
Recurrent Prostate Cancer Subsequent to Radiation Therapy
Hormone-Refractory Prostate Cancer (HRPC)
Select Drugs for Hormone-Refractory Prostate Cancer
Chemotherapy
Taxotere® (Docetaxel)
Bone Complication Treatments
Bisphosphonate Drugs
Radiation Therapy
Strategies to Enhance Recurrent Prostate Cancer Treatment
Chemotherapy
New Regimens
Phase I Clinical Trials
Combination Therapy
Gene Therapy
Targeted Therapy
Selective Endothelia A Receptor Antagonist (SERA™)
Other Select Targeted Therapies
Tyrosine Kinase Inhibitors
Anti-Angiogenic Drugs
Monoclonal Antibodies
Vaccines
Radioactive Monoclonal Antibodies

3. DRUG APPROVALS AND CLINICAL STUDIES
EMA Issues Positive Opinion to Include Data in European Label for XTANDI
Cofepris Approves Weizmann Institute Drug TOOKAD® Soluble
OncBioMune Pharmaceuticals Reports Positive Phase 1 Results of ProscaVax
FDA Accepts Xtandi sNDA by Astellas Pharma for Review
Progenics Pharmaceuticals Begins Phase 3 Clinical Trial Enrollment for 1404
FDA Grants Astrazeneca's Lynparza™ Breakthrough Therapy Designation
Nanobiotix's Investigational New Drug NBTXR3 Set for First Clinical Trial
Minomic International to Launch Human Trial of its MAb Technology
Takeda Receives NDA Approval for Leuplin
Progenics Enters into Licensing Agreement with Johns Hopkins for Clinical-Stage PSMA Agent
ZYTIGA Receives FDA Approval for Label Update
Valent Reports Long-Term results of Phase II STAND Trial of PROVENGE
OncoGeneX Pharmaceuticals to Regain Rights on Experimental Drug Custirsen from Teva
Aeterna Announces Publication of Phase 1 Data for ziptarelín doxorubicin
EC Grants Variation to Marketing Authorization for Astellas’ XTANDI
USFDA Approves New Indication for XTANDI
Advaxis Enters Into Clinical Trial Collaboration with Merck
Takeda Terminates Clinical Development of Orteronel
Arno Therapeutics Enrols First Patient into Phase I/II Trial for Onapristone

4. PRODUCT LAUNCHES
GenomeDx Biosciences Launches Decipher Biopsy Test for Prostate Cancer
Profound Medical and Siemens Sign Agreement to Launch TULSA- PROTM System
Aeterna Zentaris Begins Promotional Activities for APIFINY® Test
Biocept Launches Androgen Receptor Expression Assay for Prostate Cancer Detection
Augmenix Reports Robust Commercial Uptake of SpaceOAR® System during Radiotherapy
MDxHealth SA Launches SelectMDx Test in Europe
Bayer Launches Xofigo in Ontario
Debiopharm Group & Actavis Launch Trelstar with New, Convenient 6-Month Dosing
Analogic to Launch D&K Technologies’ BioJet™ Solution
OPKO Health Launches 4Kscore™ Test

5. RECENT INDUSTRY ACTIVITY
UCLA Sells Xtandi Rights to Royalty Pharma
Aytu BioScience Enters into Study Agreement with Hybridyne Imaging Technologies
Crown Bioscience Signs Licensing Agreement with University of York for PDX Models
Hologic Acquires DiagnoCure’s Prostate Cancer Biomarker Assets
Aeterna Zentaris Enters into Co-Marketing Agreement with Arnume
Exiqon Acquires Licensing Rights on Prostate Cancer Biomarkers from University Hospital
Mylan Sued for ANDA for Generic Version of Zytiga
Aytu BioScience Acquires Jazz Pharmaceuticals’ rights to ProstaScint
OPKO Health to Acquire Bio-Reference Laboratories
Boston Scientific to Acquire American Medical Systems' Urology Portfolio
Valeant to Acquire Dendreon's Assets
Inovio Terminates Collaboration Agreement with Roche to Independently Develop Prostate Cancer Therapy
GenomeDx Biosciences Expands Agreement with Mayo Clinic for Decipher® Prostate Cancer Classifier
Catalent Collaborates with Minomic to Develop ADC for Prostate Cancer
Orion Enters Into Global Partnership with Bayer for Development of ODM-201
Aduro BioTech Grants License to Janssen for Prostate Cancer Therapeutics
MDxHealth SA Signs Agreement with Prime Health Services

6. FOCUS ON SELECT GLOBAL PLAYERS
AbbVie, Inc. (US)
Æterna Zentaris Inc. (Canada)
Allergan plc (Ireland)
Amgen Inc. (US)
Astellas Pharma Inc. (Japan)
AstraZeneca Plc. (UK)
Bavarian Nordic (Denmark)
Bayer Healthcare AG (Germany)
Bristol-Myers Squibb Company (US)
Debiopharm Group (Switzerland)
Endo Pharmaceuticals Inc. (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
Genentech Inc. (US)
GlaxoSmithKline Plc. (UK)
Janssen Biotech, Inc. (US)
Novartis AG (Switzerland)
Pfizer Inc. (US)
Progenics Pharmaceuticals, Inc. (US)
Sanofi S.A. (France)
Spectrum Pharmaceuticals, Inc. (US)
Takeda Pharmaceutical Company Limited (Japan)
TOLMAR Pharmaceuticals, Inc. (US)
Valeant Pharmaceuticals International, Inc. (Canada)

7. GLOBAL MARKET PERSPECTIVE
Table 11: World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region/Country
US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 12: World Historic Review for Prostate Cancer Therapeutics by Geographic Region/Country
US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 13: World 14-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country
Percentage Breakdown of Dollar Sales for US, Canada, Europe, and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
Segmental Analytics
Table 14: World Recent Past, Current & Future Analysis for Hormone Therapy by Geographic Region/Country
US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 15: World Historic Review for Hormone Therapy by Geographic Region/Country
US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 16: World 14-Year Perspective for Hormone Therapy by Geographic Region/Country
Percentage Breakdown of Dollar Sales for US, Canada, Europe, and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
Table 17: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region/Country
US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 18: World Historic Review for Other Therapies by Geographic Region/Country
US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 19: World 14-Year Perspective for Other Therapies by Geographic Region/Country
Percentage Breakdown of Dollar Sales for US, Canada, Europe, and Rest of World Markets for Years 2009,
III. MARKET

1. THE UNITED STATES
   A. Market Analysis
      A. Surging US Prostate Cancer Therapeutics Market
         Prostate Cancer Stats: Opportunity Indicator
         Table 20: Prostate Cancer Incidence and Mortality in the US by Select Leading States (2016): No. of New Cancer Cases and No. of Deaths from Prostate Cancer (includes corresponding Graph/Chart)
         Table 21: Prostate Cancer Incidence/Mortality Rate in the US by Ethnicity (2008-2012) (includes corresponding Graph/Chart)
         Table 22: Male Population by Age Group in the US for the year 2014 (includes corresponding Graph/Chart)
         Table 23: Probability of Developing Invasive Prostate Cancer by Age Group in the US (2010-2012) (includes corresponding Graph/Chart)
         Other Cancer Related Statistics
         Table 24: Mortality in the US for the Year 2014 by Ailment- No. of Deaths & Percentage Breakdown for Heart Diseases, Cancer, Cerebrovascular Diseases (CVD), Chronic Lower Respiratory Diseases, Accidents (Unintentional Injuries), Alzheimer’s, Diabetes, and Others (includes corresponding Graph/Chart)
         Table 25: Cancer Deaths in the US (2016) by Site & Gender: No. of Deaths by Cancer Type Lung & Bronchus, Prostate, Colon & Rectum, and Breast (includes corresponding Graph/Chart)
         Table 26: New Cancer Case Estimates in the US by Site (2016): Percentage Share of Leading Cancer Sites in Men (includes corresponding Graph/Chart)
         Table 27: Lifetime Probability of Development of & Death from Cancer (in Men) by Type in the US, 2010-2012
         Hormone Therapy Dominates Prostate Cancer Drugs Market
         Table 28: The US Prostate Cancer Therapeutics by Leading Drug (2015)
         Percentage Share of Value Sales for Zytiga, Xtandi, Jevtana, Xofigo, Provenge & Others (includes corresponding Graph/Chart)
         High Intensity Focused Ultrasound (HIFU) Approved for Ablation of Prostate Tissue
         Clinical Trials
         Product Launches
         Strategic Corporate Developments
         Select Key Players
         B. Market Analytics
         Table 29: The US Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
         Table 30: The US Historic Review for Prostate Cancer Therapeutics by Type Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
         Table 31: The US 14-Year Perspective for Prostate Cancer Therapeutics by Type Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

2. CANADA
   A. Market Analysis
      Prostate Cancer Stats: Opportunity Indicators
      Table 32: New Cancer Cases in Canada by Site (2015): Percentage Breakdown of New Cancer Cases Diagnosed for Prostate, Colorectal, Lung, Bladder, Non-Hodgkin Lymphoma, and Others (includes corresponding Graph/Chart)
      Table 33: Prostate Cancer Incidence in Canada by Leading Province: 2015 (includes corresponding Graph/Chart)
      Table 34: Prostate Cancer Mortality in Canada by Leading Province: 2015 (includes corresponding Graph/Chart)
      Table 35: Prostate Cancer Incidence and Mortality in Canada by Age Group: 2015 (includes corresponding Graph/Chart)
      Clinical Trial
      Product Launches
      Strategic Corporate Developments
      Select Key Players
   B. Market Analytics
      Table 36: Canadian Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 37: Canadian Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 38: Canadian 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

3. EUROPE
A. Market Analysis
Awareness Drives European Prostate Cancer Therapeutics Market
HIFU Technology Gaining Momentum in Europe
Table 39: Prostate Cancer Prevalence in European Union by Diagnoses and Mortality (2012): Breakdown by Region/Country for No. of New Cases Diagnosed & No. of Deaths (includes corresponding Graph/Chart)
B. Market Analytics
Table 40: European Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region/Country
France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 41: European Historic Review for Prostate Cancer Therapeutics by Geographic Region/Country
France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 42: European 14-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country
Percentage Breakdown of Dollar Sales for France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
Table 43: European Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 44: European Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 45: European 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

3a. FRANCE
A. Market Analysis
Sanofi S.A.
A Key France-based Player.
B. Market Analytics
Table 46: French Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 47: French Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 48: French 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

3b. GERMANY
A. Market Analysis
Strategic Corporate Development
Select Key Player
B. Market Analytics
Table 49: German Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 50: German Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 51: German 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009,
2016 and 2022 (includes corresponding Graph/Chart)

3c. ITALY
Market Analysis
Table 52: Italian Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 53: Italian Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 54: Italian 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

3d. THE UNITED KINGDOM
A. Market Analysis
Table 55: Prostate Cancer Incidence in the UK by Region (2013): No. of New Cases Diagnosed in England, Wales, Scotland, and Northern Ireland (includes corresponding Graph/Chart)
Prostate Cancer Research in UK
An Insight
Need for Filling up Gaps in Provision of Care
Dearth of Clinical Researchers
Clinical Trial
Select Key Players

B. Market Analytics
Table 56: The UK Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 57: The UK Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 58: The UK 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

3e. SPAIN
Market Analysis
Table 59: Spanish Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 60: Spanish Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 61: Spanish 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

3f. REST OF EUROPE
A. Market Analysis
Product Launch
Strategic Corporate Development
Select Key Players

B. Market Analytics
Table 62: Rest of European Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 63: Rest of European Historic Review for Prostate Cancer Therapeutics by Type
Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 64: Rest of European 14-Year Perspective for Prostate Cancer Therapeutics by Type
Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
4. REST OF WORLD
A. Market Analysis
Minimally Invasive Devices to Gain Share in Emerging Markets
Cancer Market in Asia
Australia
India
Table 65: New Incidence Rate of Prostate Cancer (Rate per Million Population) in Asia-Pacific and Latin America for 2012
Table 66: 5-Year Net Survival Rates (%) for Prostate Cancer among Adults 15 yrs of Age and Older (2005-2009) in Select Asian and Latin American Countries (includes corresponding Graph/Chart)
Clinical Trials
Select Key Players
B. Market Analytics
Table 67: Rest of World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 68: Rest of World Historic Review for Prostate Cancer Therapeutics by Type Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 69: Rest of World 14-Year Perspective for Prostate Cancer Therapeutics by Type Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 76 (including Divisions/Subsidiaries 84)
The United States (47)
Canada (6)
Japan (4)
Europe (23)
- France (5)
- Germany (3)
- The United Kingdom (5)
- Rest of Europe (10)
Asia-Pacific (Excluding Japan) (4)

Ordering:
Order Online - http://www.researchandmarkets.com/reports/992765/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Prostate Cancer Therapeutics - Global Strategic Business Report
Web Address: http://www.researchandmarkets.com/reports/992765/
Office Code: SC2GGX96

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 4500</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td></td>
<td>USD 6300</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 10 Users:</td>
<td></td>
<td>USD 8550</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 15 Users:</td>
<td></td>
<td>USD 10800</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________________________ Last Name: _____________________________
Email Address: * _______________________________________
Job Title: ____________________________________________
Organisation: _________________________________________
Address: _____________________________________________
City: __________________________________________________
Postal / Zip Code: _____________________________________
Country: ______________________________________________
Phone Number: _________________________________________
Fax Number: ___________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>Sort code</th>
<th>Swift code</th>
<th>IBAN number</th>
<th>Bank Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>833 130 83</td>
<td>98-53-30</td>
<td>ULSBIE2D</td>
<td>IE78ULSB98533083313083</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World